Question

هل علاج الخلايا الجذعية لـ ارتفاع ضغط الدم موافق عليه من قبل FDA؟

The FDA has not approved a stem-cell or exosome therapy specifically for arterial hypertension as a licensed product. Investigational MSC protocols are registered with the NIH but remain unapproved. The EMA likewise has not granted a marketed hypertension-specific stem-cell therapy. Established antihypertensive drug classes (ACE inhibitors, ARBs, calcium-channel blockers, diuretics) remain the FDA gold standard and evidence-based first-line treatment. Any marketed stem-cell therapy for hypertension should be scrutinised; unapproved direct-to-consumer claims abound in this prevalent condition.

How stem cells are studied for Arterial Hypertension

Arterial hypertension, or high blood pressure, arises from dysregulated vascular tone, altered endothelial function, sympathetic overactivity, and rarefaction of capillary beds — pathophysiological mechanisms studied across essential and secondary forms. Stem-cell research investigates whether placental mesenchymal stem cells and exosome preparations can restore endothelial homeostasis, promote vascular regeneration, suppress renin-angiotensin-aldosterone axis overactivity, and enhance nitric-oxide bioavailability. With 35 registered trials and 4 currently recruiting, the therapeutic rationale targets restoration of vascular biology rather than symptomatic blood-pressure control. Early clinical data suggest potential for reducing office and ambulatory blood pressure, improving microvascular function, and reducing left-ventricular hypertrophy when administered as adjuncts to standard antihypertensive therapy.

هل أنا مرشح؟ → · Arterial Hypertension: full overview → · تكلفة ارتفاع ضغط الدم → · Cost →

تم المراجعة الطبية بواسطة فريق التحرير StemCellAtlas مع Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) من عيادة الشريك Stem Plus (صوفيا)، وفقاً لـ ISSCR و FDA و EMA. Educational information, not medical advice; figures indicative.

علاج خلوي بمعايير أوروبية وبأسعار في المتناول.

طب تجديدي معتمد GMP في قلب الاتحاد الأوروبي — من 3,000 إلى 8,000 يورو، جزء بسيط من أسعار أمريكا أو ألمانيا. بروتوكولات مخصصة لمرضى من أكثر من 50 دولة.

مراجعة طبية مجانية